Skip to main content
Premium Trial:

Request an Annual Quote

Evogene Raises Nearly $74M in US IPO

NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

The firm has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same offering price per share.

The Israel-based company, which also trades on the Tel Aviv Stock Exchange, filed to go public in the US in September, saying at the time that it intended to offer $60 million of its shares.

Evogene said that agricultural products giant Monsanto has agreed to purchase 813,560 ordinary shares as part of the offering for approximately US$12 million.

Evogene's shares are expected to begin trading today on the New York Stock Exchange under the symbol "EVGN."

Credit Suisse Securities and Deutsche Bank Securities acted as joint book-running managers on the planned offering, while Oppenheimer and Piper Jaffray were co-managers.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.